- Home
- HRMY vs GENI Comparison
HRMY vs GENI Comparison
Compare HRMY & GENI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- GENI
- Stock Information
- Founded
- HRMY 2017
- GENI 2016
- Country
- HRMY United States
- GENI United Kingdom
- Employees
- HRMY N/A
- GENI N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- GENI Services-Misc. Amusement & Recreation
- Sector
- HRMY Health Care
- GENI Consumer Discretionary
- Exchange
- HRMY Nasdaq
- GENI Nasdaq
- Market Cap
- HRMY 2.2B
- GENI 2.1B
- IPO Year
- HRMY 2020
- GENI N/A
- Fundamental
- Price
- HRMY $34.56
- GENI $9.10
- Analyst Decision
- HRMY Strong Buy
- GENI Strong Buy
- Analyst Count
- HRMY 8
- GENI 11
- Target Price
- HRMY $54.38
- GENI $11.23
- AVG Volume (30 Days)
- HRMY 557.4K
- GENI 1.9M
- Earning Date
- HRMY 02-25-2025
- GENI 03-04-2025
- Dividend Yield
- HRMY N/A
- GENI N/A
- EPS Growth
- HRMY N/A
- GENI N/A
- EPS
- HRMY 2.11
- GENI N/A
- Revenue
- HRMY $681,879,000.00
- GENI $462,535,000.00
- Revenue This Year
- HRMY $25.11
- GENI $26.20
- Revenue Next Year
- HRMY $19.19
- GENI $15.34
- P/E Ratio
- HRMY $16.46
- GENI N/A
- Revenue Growth
- HRMY 25.83
- GENI 18.25
- 52 Week Low
- HRMY $28.14
- GENI $4.91
- 52 Week High
- HRMY $41.61
- GENI $10.33
- Technical
- Relative Strength Index (RSI)
- HRMY 35.54
- GENI 47.55
- Support Level
- HRMY $37.03
- GENI $8.91
- Resistance Level
- HRMY $39.91
- GENI $10.21
- Average True Range (ATR)
- HRMY 1.34
- GENI 0.35
- MACD
- HRMY -0.58
- GENI 0.01
- Stochastic Oscillator
- HRMY 9.86
- GENI 34.99
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.